# Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer

> **NCT00441571** · PHASE1 · UNKNOWN · sponsor: **Cytogen Corporation** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** 177Lu-CYT-500

## Key facts

- **NCT ID:** NCT00441571
- **Lead sponsor:** Cytogen Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2007-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441571, "Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00441571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*